Benitec Biopharma Inc.
BNTC$13.48
$-0.30 (-2.18%)-2.18%
Pre-MarketLoading chart...
IndexN/A
Market Cap0.46B
Enterprise Value0.33B
Income$-0.04B
Sales$0.00B
EmployeesN/A
P/E-11.82
P/S0.00
P/B4.35
P/C-17.95
EV/EBITDA-7.90
EV/SalesN/A
EPS (ttm)-1.14
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.05M
Shs Outstand0.03B
Change-2.18%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $75.00K | $73.00K | $59.00K | $97.00K | $11.32M | $455.45K |
| Cost of Revenue | $396.00K | $343.00K | $381.00K | $9.00K | $123.00K | $-185.00K | $426.51K | $331.30K |
| Gross Profit | $-396.00K | $-343.00K | $-306.00K | $64.00K | $-64.00K | $282.00K | $10.89M | $124.15K |
| Gross Margin | N/A | N/A | -408.00% | 87.67% | -108.47% | 290.72% | 96.23% | 27.26% |
| Operating Expenses | $41.37M | $22.25M | $18.77M | $17.92M | $13.53M | $8.56M | $8.89M | $8.68M |
| Operating Income | $-41.77M | $-22.60M | $-19.08M | $-17.85M | $-13.60M | $-8.28M | $2.00M | $-8.55M |
| Operating Margin | N/A | N/A | -25441.33% | -24457.53% | -23044.07% | -8537.11% | 17.70% | -1877.75% |
| Net Income | $-37.92M | $-21.75M | $-19.56M | $-18.21M | $-13.88M | $-8.27M | $2.87M | $-8.55M |
| Net Margin | N/A | N/A | -26082.67% | -24942.47% | -23528.81% | -8529.90% | 25.34% | -1877.42% |
| EPS (Basic) | $-1.05 | $-2.68 | $-14.12 | $-19.31 | $-27.27 | $-69.09 | $28.45 | $-103.61 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $99.59M | $52.21M | $4.46M | $5.97M | $21.38M | $11.74M | $19.21M | $15.68M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.30M | $4.96M | $4.26M | $3.09M | $1.37M | $1.51M | $2.64M | $1.91M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $97.30M | $47.25M | $202.00K | $2.88M | $20.01M | $10.24M | $16.57M | $13.77M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $97.30M | $47.25M | $202.00K | $2.88M | $20.01M | $10.24M | $16.57M | $13.77M |
| Total Liabilities & Stockholders Equity | $99.59M | $52.21M | $4.46M | $5.97M | $21.38M | $11.74M | $19.21M | $15.68M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-37.92M | $-21.75M | $-19.56M | $-18.21M | $-13.88M | $-8.27M | $2.87M | $-8.55M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-23.59M | $-19.40M | $-18.01M | $-15.90M | $-12.83M | $-7.54M | $4.79M | $-8.55M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Updateglobenewswire.com Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meetingglobenewswire.com Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)globenewswire.com Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conferenceglobenewswire.com Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgradeseekingalpha.com Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Responseglobenewswire.com Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 50,000 Sharesdefenseworld.net Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Sharesdefenseworld.net
Show 12 more stories
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?zacks.com Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Purchases 10,215 Shares of Stockdefenseworld.net Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Knowzacks.com Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)zacks.com Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Updateglobenewswire.com Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others247wallst.com Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offeringglobenewswire.com Benitec Biopharma Inc. Announces Proposed Public Offeringglobenewswire.com Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301globenewswire.com Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophyglobenewswire.com Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of “Moderate Buy” by Analystsdefenseworld.net Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Updateglobenewswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
Discover more
You may be interested in